期刊文献+

降低血脂保护糖尿病肾病患者肾功能的观察 被引量:3

Observation of Protecting the Renal Function in Patients with Diabetic Nephropathy by Reducing Serum Lipids
下载PDF
导出
摘要 目的应用阿托伐他汀降低血脂水平,观察其对保护糖尿病肾病患者肾功能的作用。方法选择糖尿病肾病伴有高脂血症患者160例,随机分为治疗组82例和对照组78例。治疗组患者予阿托伐他汀控制血脂。慢性肾衰竭药物治疗方案两组相同。观察期限12个月,比较两组患者血脂与肾功能的差异。结果治疗组血脂比对照组明显下降(P<0.001),eGFR下降明显低于对照组(P<0.01)。结论糖尿病肾病患者通过降低血脂水平,可明显延缓肾衰竭的进展,应尽早降低血脂至正常水平。 Objective To investigate the effect of atorvastatin in protecting the renal function in patients with diabetic nephropathy by reducing serum lipids.Methods 160 patients of diabetic nephropathy with hyperlipemia were divided into treatment group(n=82) and control group(n=78) randomly.Atorvastatin was taken in the treatment group.The drug treatment programs of chronic renal failure were the same in the two groups.At the observation period of 12 months,serum lipids and renal function were compared between the two groups.Results Serum lipids(P〈 0.001) and the fall of eGFR(P〈 0.01) in the treatment group were lower than those in the control group significantly.Conclusion Reducing serum lipids in patients with diabetic nephropathy can delay the progress of renal failure.Serum lipids shall be controlled to standard level as soon as possible.
出处 《临床医学工程》 2011年第5期707-708,共2页 Clinical Medicine & Engineering
关键词 血脂 糖尿病肾病 肾功能 阿托伐他汀 Serum lipids Diabetic nephropathy Renal function Atorvastatin
  • 相关文献

参考文献15

  • 1National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [J] . Am JKidney Dis, 2002, 39 (2 Suppl 1) : S1-266.
  • 2Kaysen GA. Dyslipidemia in chronic kidney disease: Causes and consequences [J] . Kidney Int, 2006, 70 (Supplement 104S) :S55-S58.
  • 3Rabkin R. Diabetic nephropathy [J] . Clin Comerstone, 2003, 5:1-11.
  • 4Fogo AB. Progression and potential regression of glomerulosclerosis [J] . Kidney lnt, 2001, 59 (2) : 804-819.
  • 5American Diabetes Association. Standards of medical care in diabetes 2006 (position statement) [J] . Diabetes Care, 2006, 29 (suppl 1) : S4-S42.
  • 6McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetics [J] . Diabetics, 2002, 51 (1) : 7-18.
  • 7Kosch M, Barenbrock M, Suwelack B, et al. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient [J] . A m J Kidney Dis, 2003, 41: 1088-1096.
  • 8Panichi V, Paoletti S, Mantuano E, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients [ J] . Nephrol Dial Transplant, 2006, 21 (2) : 337-344.
  • 9Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men [J] . J Am Soc Nephrol, 2003, 14 (8) : 2084-2091.
  • 10Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP) [J] . Am JKidney Dis, 2003, 42 (1) : 22-35.

同被引文献29

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部